

**CURRICULUM VITAE**  
**LISA GEORGIANNE RIDER, M.D.**

**PRESENT POSITION**

Deputy Unit Chief, Environmental Autoimmunity Group, Office of Clinical Research,  
National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH)  
Bldg 10, CRC, Room 4-2352, 10 Center Drive, MSC 1301  
Bethesda, MD 20892-1301  
Phone: (301) 451-6272  
FAX: (301) 451-5588  
Email: riderl@mail.nih.gov

**EDUCATION**

1983-87            **M.D.**, Duke University School of Medicine, Durham, N.C.

1979-83            **A.B.**, Duke University, Durham, N.C.  
Chemistry with Biochemical Specialization

1979                **High School Diploma**, Ridge High School, Basking Ridge, NJ

**POST-GRADUATE TRAINING**

July 1991-        **Pediatric Rheumatology Fellow** (clinics), Children's Hospital National  
June 1993        Medical Center, Washington, DC

March 1991-      **Clinical Associate**, Laboratory of Chemical Immunology (Dr. Henry Metzger),  
July 1993        Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal  
and Skin Diseases, National Institutes of Health, Bethesda, Maryland

Aug 1990-        **Pediatric Rheumatology Fellow**, University of Washington/Children's  
Feb 1991        Hospital and Medical Center, Seattle, WA

July 1987-        **Internship/Residency in Pediatrics**, University of Washington/Children's  
July 1990        Hospital and Medical Center, Seattle, WA

**PROFESSIONAL POSITIONS**

Sept 2003-       **Deputy Unit Chief**, Environmental Autoimmunity Group (EAG), Office of Clinical  
Present           Research, National Institute of Environmental Health Sciences, National  
Institutes of Health, Bethesda, MD

**Duties/Accomplishments:**

- Supervisory and management responsibilities for administration of the clinical research unit together with the unit chief. Serve as acting unit chief 60 - 75 days per year, while he is on travel or leave. Duties include unit operations, research directions and communications with collaborators within and outside NIH, budget management, personnel issues, patient care administration, ongoing work on development and management of 2 large Oracle databases for clinical research data, and planning of duties for other unit personnel. Plan and execute all research for the unit together with the team.
- Principal investigator of myositis studies. Lead investigator in study of calcinosis. Associate investigator in studies of environmental factors associated with etiology and pathogenesis of systemic rheumatic diseases and in infliximab clinical trial for myositis. Steering Committee member of new clinical trial of rituximab for adult and juvenile myositis.
- Precept research fellows and instruct 8 Unit personnel concerning ongoing basic and clinical research. Directly supervising:
  - Mona Shah- PhD candidate student, George Washington University Department of

- Epidemiology (2008 – present)
- Gulnara Mamyrova, MD PhD – Clinical Research Fellow; recipient DC Rheumatism Society Fellows Research Award (2005-2007)
- Leora Vegosen – PhD Student (2008 – present) and Master's of Environmental Science student (2004-05), Johns Hopkins University School of Public Health; NIEHS 2004 Summers of Discovery student; Recipient of 2005-06 ACR Research and Education Foundation Medical/Graduate Student Achievement Award
- Michael Harris-Love PT PhD (2005- present): faculty member, DC VA Medical Center; studies on muscle strength and function
- Jonathan Chipman- NIEHS 2007 Summers of Discovery Student, completing BA in statistics at Brigham Young University
- Kim Nguyen (2008-09), Amy Li (2007 -08): student volunteers, Montgomery Blair Math Science high school magnet student- senior research project
- Lan Wu: 2007 -09: Johns Hopkins University college student, volunteer
- Jason Monroe – NIEHS 2005 Summers of Discovery student, PhD student in Statistics, UCLA
- Melvina Evereklian – Summer student, RN student, Univ. Maryland
- Ellen Caruso and Vanessa Voss, RN – Database managers of NIEHS myositis and IMACS studies
- Attending physician for all of the unit's pediatric patients, including clinical evaluation, treatment and communications with referring physicians. NIEHS has been one of the five most active pediatric institutes at the NIH Clinical Center.
- Co-chair of International Myositis Assessment and Clinical Studies (IMACS) Group. Developed group's web site to provide public access to outcome measures, assessment tools and related educational materials. Building a database repository of myositis clinical trials and natural history studies, including an on-line Oracle database of outcome measures and study demographics. Organize group's annual meeting and direct all correspondence to members.
- NIEHS representative to NIH Clinical Center committees, particularly on pediatric care issues. NIH moved the hospital to the new Clinical Research Center and opened a NIH-wide multidisciplinary pediatric clinic in 2005.
- Advisory board and executive section member of national advisory boards, including ACR Pediatric Executive Section, pediatric rheumatology collaborative trials groups, and The Myositis Association.
- Recent research findings have included development of definitions of improvement as a primary composite endpoint for myositis clinical trials, discovery of a novel autoantibody that is the most frequent antibody present in juvenile dermatomyositis patients, development and validation of novel outcome measures for juvenile myositis, and discovery of new immunogenetic risk factors for juvenile myositis.
- Senior editor of a book on juvenile myositis involving more than 70 health professionals.
- Invited for multiple national and international lectureships at meetings and prominent medical schools.
- Frequent advisor to NIH and other physicians and patients throughout the world, patient support groups, DHHS agencies, and colleagues at medical schools in the evaluation and care of challenging patients with pediatric rheumatic diseases, and in review of scientific activities related to autoimmunity in children.

January 2001–	<b>Senior Clinical Investigator and Medical Officer,</b> Environmental Autoimmunity Group (EAG), Office of Clinical Research, National Institute of
September 2003	Environmental Health Sciences, National Institutes of Health, Bethesda, MD

Duties/Accomplishments:

- Design and execute clinical research, assist Unit Chief in administration of EAG, supervise and mentor personnel within the group.

- Principal investigator of myositis study and lead investigator of calcinosis study. Co-investigator of research protocols examining environmental risk factors for autoimmune diseases and novel therapeutic agent for myositis. Contributed to study design and questionnaire development, design of Oracle databases for the studies.
- Attending physician for all pediatric patients admitted to EAG research protocols, plan research and clinical studies for patients, and communicate results to referring physicians.
- Attending physician and consultant in pediatric rheumatology clinic at Walter Reed Army Medical Center (until Aug 2004).
- Co-chair and co-founder of International Myositis Assessment and Clinical Studies (IMACS) Group, which has developed new instruments to assess myositis. Led 3 international workshops on outcome measures for myositis, which resulted in new standards for conduct and reporting of clinical trials in myositis, and will establish new clinical practice standards. Developed internet site for IMACS to house member applications, public use of validated tools and training materials, meeting presentations, ongoing studies.
- Invited for multiple national and international lectureships at meetings and prominent medical schools.
- Supervisor and mentor to:
  - Gulnara Mamyrova MD PhD – Clinical Research Fellow
  - April Bingham MD- Visiting pediatric rheumatology fellow, Columbia University
  - Melvina Evereklian- RN student; volunteer. 2005 Beacon conference award recipient.
  - Lauren Komarow – NIEHS 2003 Summers of Discovery student, MS in biostatistics, Univ. Michigan; currently employed at Harvard School of Public Health
  - Adam Schiftenbauer – NIEHS 2002 Summers of Discovery student, BA Univ. Chicago; currently MD PhD student at Penn State University
  - Tina Sanghvi – NIEHS 2002 Summers of Discovery student and 2003 summer student, BA, Duke Univ.; currently MD student at Univ. Iowa
  - Ellen Caruso- part-time volunteer for data management of myositis study.

Projects have included validation of clinical outcome measures and surrogate laboratory measures to assess disease activity in myositis, new autoantibodies in myositis, features of lipodystrophy associated with juvenile myositis, immunogenetic loci as risk factors for myositis, HLA typing of juvenile myositis patients.
- Teach NIAMS and NIEHS adult rheumatology fellows, students, post-docs in patient conferences, patient presentations, and quarterly lectures on juvenile dermatomyositis. Instruct EAG staff, including other researchers, clinicians, nurse and support staff concerning ongoing research and clinical studies of patients.
- Assist the Unit Chief in administration of unit, including serving as Acting Chief up to 30 days per year while he is on travel or leave. Developed all SOPs and procedures for pediatric patients enrolled in unit's research studies. Assisted the chief in establishing a new clinical research unit on the NIH campus in Bethesda, MD, with our institute in North Carolina, including defining space for offices and clinics, hiring of unit personnel, developing SOPs.
- NIEHS representative to NIH Clinical Center, IRB and data safety monitoring board committees; advisor to DHHS Children's Longitudinal Environmental Health Study (National Children's Study) and Immunity, Infections and Vaccines Working Group; advisory board and executive section member of national pediatric rheumatology and patient support groups, and the FDA.
- Senior editor of a book on juvenile myositis involving more than 70 health professionals.
- Frequent advisor to NIH and other physicians and patients throughout the world, patient support groups, DHHS agencies, and colleagues at medical schools in the evaluation and care of challenging patients with pediatric rheumatic diseases, and in review of scientific activities related to autoimmunity in children.

September 1996 – **Medical Officer and Staff Scientist**, Division of Monoclonal Antibodies, December 2000 Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Bethesda, MD

Duties/Accomplishments:

- Lead investigator of 2 large multi-center nationwide studies of the juvenile myositis syndromes, including data collection and analysis. Principal investigator of NIH research protocol. Discovered microchimerism is frequently present in children with myositis and potentially important in pathogenesis. Developed novel instruments to assess myositis outcomes. Identified a number of immunogenetic polymorphisms, as risk factors for myositis in adults and children. Defined a number of clinical, immunologic and environmental subsets of juvenile myositis.
- Supervised and mentored 4 students (Abhijit Pal and Adam Schiffenbauer – International Baccalaureate Program, Richard Montgomery High School; Ben Laskin, BA, Duke Univ., currently MD student Univ. Maryland; Elizabeth Zachariah, BA, Univ. Maryland) and 1 volunteer (Ellen Caruso) who participated in data management and analysis of clinical studies, or HLA typing of juvenile myositis patients and processing tissue samples from patients.
- Invited lectureships at national meetings and medical schools.
- Chaired licensure committee for Etanercept for juvenile rheumatoid arthritis, and served on other licensure committees for anti-TNF $\alpha$  therapies for rheumatoid arthritis. Involved in policy making for rheumatic diseases and pediatrics at the FDA. Authored Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Pediatric Clinical Trials Guidance Documents; participated in drafts of 1998 Pediatric Regulation. Policies developed to apply pediatric use labeling regulation to juvenile rheumatoid arthritis resulted in a large number of IND and NDA submissions for this orphan pediatric population. Consultant reviewer for licensure of several drugs for juvenile rheumatoid arthritis, vaccine adverse events, blood product labeling for pediatric use, and silicone implant adverse events. Represented FDA on Pediatric Rheumatology Collaborative Study Group Advisory Council. Presentations to Arthritis Advisory Committee. Regulatory review of product and INDs.
- Attending physician and consultant in pediatric rheumatology clinic at Walter Reed Army Medical Center.
- Frequent Advisor to physicians and patients throughout the world, patient support groups, DHHS agencies, and colleagues at medical schools in the evaluation and care of challenging patients with pediatric rheumatic diseases, and in review of scientific activities related to autoimmunity in children.

September 1993 - **Medical Officer**, Division of Cellular and Gene Therapies, CBER, FDA, Bethesda, MD

Sept 1996

Duties/Accomplishments:

- Planned and initiated two large nationwide studies of juvenile myositis.
- Principal investigator of NIH juvenile myositis research protocol.
- Saw complex patients in research study and communicated results to referring physicians. Attending physician and consultant in pediatric rheumatology clinic at Walter Reed Army Medical Center.
- Participated in laboratory research studies of autoantibodies and immunogenetics of adult and juvenile myositis.
- Supervised and mentored three students, including Dr. Ejaz Shamim, who received the American College of Rheumatology Medical Student Research Fellowship Award (1995).
- Product and clinical reviewer of biologic therapeutic agents. FDA Rheumatology Working Group and Pediatric Use Working Group. Consultant to Agency on pediatric rheumatic disease issues. Co-chair of FDA workshop on juvenile rheumatoid arthritis (1996).

### **CLINICAL RESPONSIBILITIES AND HOSPITAL APPOINTMENTS**

2001 – present: Senior Clinical Staff, NIEHS, National Institutes of Health, Bethesda, MD  
April 2008 – present: Attending Physician, Myositis Clinic, George Washington University (2 days/month)  
Dec 2005 – June 2007: Visiting Consultant and Attending Physician, Rheumatology, Children's National Medical Center (1 day/month)  
1994 -August 2005: Attending Physician, Pediatric Rheumatology, Walter Reed Army Medical Center, Washington, DC (1 – 2 days/month)  
Oct 1993 – 2001: Junior Clinical Staff, NIAMS, National Institutes of Health, Bethesda, MD (varying: 1 day/month – 1 day/week)

### **ACADEMIC APPOINTMENTS**

Sept 2008 - June 30, 2009 **Clinical Professor**, Department of Medicine, George Washington University, Washington, DC  
Nov 2002 – present **Adjunct Associate Professor**, Department of Pediatrics, Uniformed Services University of Health Sciences (USUHS), Bethesda, MD  
March 1994 - **Assistant Professor**, Department of Pediatrics, Uniformed Services University of Health Sciences, Bethesda, MD  
Nov 2002

#### **Duties/Accomplishments:**

Attending physician and consultant in Pediatric Rheumatology Clinic at Walter Reed Army Medical Center, which receives nationwide and worldwide referrals for military personnel. Supervise, teach and lecture adult rheumatology fellows, pediatric residents, USUHS medical students rotating through clinic. Consult with military physicians in US and worldwide (esp. Germany) on issues of care of complex patients with pediatric rheumatic diseases.

July - Aug **Acting Instructor**, Div of Immunology/Rheumatology, Department of Pediatrics,  
1993 Univ. Washington/Children's Hospital and Medical Center, Seattle, WA

### **US PUBLIC HEALTH SERVICE APPOINTMENTS AND ACTIVITIES**

Captain (7/05 – present); Permanent Captain (7/07 – present)  
Permanent Commander (9/03 – 7/05)  
Assimilation into Regular Corps: Permanent Lieutenant Commander (4/12/02 – 9/03)  
Commander (7/98 – 4/02)  
Lieutenant Commander (10/91 – 6/93, 9/93 – 7/98)  
Senior Assistant Surgeon (2/28/91 – 10/91)  
Commissioned as a Corps Officer 2/28/91.

Commissioned Corps Readiness Force (December 2003 – present)  
Status: Active; Roster: Fully Deployable; Primary Role: NIH Research Roster  
Training/Skills: Completed 14 basic readiness level core training modules and 6 FEMA modules  
BLS certified. President's Fitness Challenge (completed August, 2004 and Dec 2006)  
Deployments: President Ronald Reagan State Funeral (June 2004)  
Mentor to Medical Officers, Physician's Professional Advisory Committee (2004)  
Physician's Professional Advisory Committee Subcommittee on Mentoring (2004)  
Public Health Service Medical Review Board member (June 2002, December 2003)  
Commissioned Officers Association (2003 – present)

### **CERTIFICATION**

Pediatric Advanced Life Support (Jan 2007)  
Basic Life Support, American Heart Association (2003 – present)  
American Board of Pediatrics, Certification in Pediatric Rheumatology (1994 - 2001, recertified for 2002 – 2008, Certificate No 000113; recertified 2009 – 2013, certificate No. 00113)  
American Board of Pediatrics (1990, re-certified for 1998 - 2004, Certificate No. 045457)  
FLEX (1987)

### **PROFESSIONAL LICENSE**

Maryland, #D46950, 12/30/94 - present (expires 9/30/09)  
District of Columbia, #MD19164, 1991 - April, 1997; # MD035811, 10/27/2005 - present  
Virginia, #0101052145, 3/1/95 - 6/30/96  
Washington, #MD00027469, 06/90 - 2/14/94  
Federal DEA Registration Number, #BR5314543

### **HONORS AND AWARDS**

2008	America's Top Pediatricians (Consumer's Research Council of America)
2007	Hero Certificate, Cure JM Foundation ("For dedication to finding a cure for juvenile myositis")
2006	Elected member of the Henry Kunkel Society
2006	Certificate of Appreciation, US Public Health Service ("For exceptional performance in response to the USPHS Transformation objectives and mission by developing resources to mentor the professional development of Commissioned Corps physicians")
2005 – 2008	Who's Who in America
2005, 2006	Who's Who of American Women
2004	Commendation Medal, US Public Health Service ("For superior service in identifying the presence of microchimerism in juvenile-onset myositis")
2004 – 2007	Who's Who in Medicine and Healthcare
2004	National Register's Who's Who, Executive and Professionals 2004 – 2005 edition
2002	Regular Corps Ribbon, US Public Health Service
2001	National Registry of Who's Who, Published 2001 edition
2000	Commendation Medal, US Public Health Service ("For exemplary performance of duty" in clinical review and policy development)
1999	Outstanding Unit Citation, US Public Health Service ("For innovative collaboration with academia, industry and the public in the development of programs for the treatment of rheumatoid arthritis")
1999	Unit Commendation, US Public Health Service ("For significant and exceptional performance in the review and licensing of new anti-TNF therapies for autoimmune disease")
1998	Achievement Medal, US Public Health Service ("For validating the usefulness of clinical tools to assess disease activity in juvenile myositis with implications for many other pediatric and orphan diseases")
1998	Bicentennial Unit Commendation, US Public Health Service
1985-86	Eugene Stead Research Fellowship, Duke University School of Medicine
1983	Phi Beta Kappa, Summa cum laude, Duke University

### **PROFESSIONAL ORGANIZATIONS**

Henry Kunkel Society (2006 – present)  
Clinical Immunology Society (2006 – present)  
Section on Environmental Health, American Academy of Pediatrics (2004 - present)  
Section on Uniformed Services, American Academy of Pediatrics (2000 - present)  
American Medical Association (1996 - present)  
Pediatric Rheumatology Subsection, American College of Rheumatology (1994 - present)  
Section on Pediatric Rheumatology, American Academy of Pediatrics (1994 - present)  
Washington DC Rheumatism Society (1991 – 1994, 2003 - present)  
American College of Rheumatology (1990 - present)  
American Academy of Pediatrics (1990 - present)

### **PROTOCOL INVESTIGATIONS**

Principal Investigator, Studies in the Natural History and Pathogenesis of the Idiopathic Inflammatory Myopathies of Childhood, NIEHS, National Institutes of Health, Bethesda, MD (NIEHS 94-E-0165)

(1994 – 2001 as NIAMS protocol, 2001 – present as NIEHS protocol)  
 Co-Investigator, “Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis” (NIEHS 07-E-0012) (2006 – present)  
 Co-Investigator, “Studies in the Natural History and Pathogenesis of Adult Myositis” (NIAMS 91-AR-0196), (2005 – present)  
 Co-Investigator, “Pathogenic Studies in Families with Twins or Siblings Discordant for Systemic Rheumatic Disorders” (NIEHS 03-E-0099) (2003 – present)  
 Co-Investigator, “Studies on Tissues from Patients with Fibrous Dysplasia of Bone/McCune Albright Syndrome and Other Disorders of Calcified Tissues” (NIDR 97-D-0055) (2002 – present)  
 Co-Investigator, “A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients with Dermatomyositis and Polymyositis” (NIAMS 02-AR-0156) (2002 – present)  
 Co-Investigator, “Studies in the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases” (FDA RIHSC CBER #121; NIEHS 05-E-N200) (1994 – present); Protocol includes Principal Investigator, Childhood Myositis Heterogeneity Collaborative Study, a registry of over 400 juvenile idiopathic inflammatory myopathy patients with clinical information, cell and serum bank, limited biopsy specimens.

### **GRANT SUPPORT**

2006 - present Inter-agency agreement, NIAMS, Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathies (NIEHS as enrollment site, \$515,586)  
 2005 - present American College of Rheumatology, Development of Outcome Measures for Myositis (\$15,000 to support database development and management)  
 2004 – 2007 Supervisor for Research Fellowship of Dr. Gulnara Mamyrova, Cure JM Foundation (salary support for 3 years; no funds being received by me or NIEHS)  
 2002 – 2004 Supervisor for Research Fellowship of Dr. Gulnara Mamyrova, The Myositis Association (salary support for 2 years; no funds being received by me or NIEHS)  
 2001, 2002 Co-Principal Investigator, NIH Office of Rare Diseases and NINDS funding for 2 workshops on Outcome Assessment and Clinical Trial Design in the Idiopathic Inflammatory Myopathies (\$25,000 each year).  
 2001 – 2002 Co-Investigator, NIAMS R21 grant to Dr. Ann Reed, “Finalization of Outcomes and Design Issues for Myositis Trials” (\$83,000; no funds being received by me or NIEHS)  
 1985-86 Pharmaceutical Manufacturer's Medical Student Research Fellowship in Pharmacology - Clinical Pharmacology

### **COMMITTEES AND ADMINISTRATIVE EXPERIENCE**

Resource Committee, NIH Clinical Center Barriers to Clinical Research Working Group (2008 - )  
 Pediatric Rheumatology Study Section Chair, American College of Rheumatology (2006 – 2009)  
 Communications Committee, Clinical Immunology Society (2006 – 2009)  
 Editorial Board, Table of Biologic Therapies, Clinical Immunology Society (2008 – 2009)  
 Member and lead investigator of pediatric studies, International Myositis Genetics Consortium (MyoGen) (2006 – present)  
 Steering Committee, ACR-EULAR International Myositis Classification Criteria Project for the Idiopathic Inflammatory Myopathies (2004 – present)  
 Medical Advisory Board Member, The Myositis Association (1996 - present); Vice Chair (2005 –2007), Chair, Nominating Committee (2001 –2006), Research Committee (2006 - present), Chair Research Committee (2008- present)  
 Consultant, NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease (2004 – 2007)  
 Executive Council, Pediatric Subsection, American College of Rheumatology (2003 – 2007); Vice Chair (2006 – 2008)  
 NIEHS representative, NIH Clinical Research Center Pediatric Partners Care Team (2003 – present)  
 NIEHS representative to NIH Pediatric Care Committee (2002 – present); Subcommittee on Normal Childhood Laboratory Values (2003- 2006); Subcommittee on Infection Control Policies at Children's Inn (2004 – 2005)  
 NIEHS Code Red Team member for NIH Clinical Center; Designated evacuation safety leader for EAG,

organizing annual safety and evacuation training (2003 – present)  
 Steering Committee, Trial of Rituximab in Adult and Juvenile Idiopathic Inflammatory Myopathies (2002 – present)  
 Children's Longitudinal Environmental Health Study (National Children's Study), Immunity, Infections and Vaccines Working Group (2002 – 2005)  
 Childhood Arthritis and Rheumatology Research Alliance (CARRA), Member: Juvenile Dermatomyositis Scientific Group, Translational Research Working Group (2002 – present); Disease registry working group (2008- present)  
 Member and NIH Representative, Advisory Council, Pediatric Rheumatology Collaborative Study Group (2001 – present)  
 Member, NIH Pediatric Consortium (2001 – present), NIH Muscle Interest Group (2001 – present)  
 Member, Search Committee for NIEHS Staff Clinician (2001 – 2002)  
 Co-Chair and Co-Founder, International Myositis Assessment and Clinical Studies (IMACS) Collaborative Study Group (2000 - present). Organizer of 3 international IMACS Workshops (2001-2003) and annual meetings. Developed IMACS internet site to make publicly available IMACS outcome measures, training modules and a database repository of myositis clinical trials.  
 Abstract Selection Committee, Pediatric Rheumatology (1998), Myositis/Myopathies (2002, 2004), American College of Rheumatology  
 Meeting Organizer and Co-Chair, FDA Juvenile Rheumatoid Arthritis Workshop, Bethesda, MD (July 23, 1996)  
 Advisor, the National Dermatomyositis Support Group, 1994-1996  
 Juvenile Dermatomyositis American College of Rheumatology Working Group (founding chair) (1993 - present)

### **FDA Regulatory Activities**

Special Government Employee Consultant to FDA, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Bethesda, MD (2003 –2005): consultant on INDs for biologic therapies in children with pediatric rheumatic diseases  
 Guest Worker (Special Government Employee Consultant to FDA under Inter-Agency Agreement), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Bethesda, MD (2001 - 2002): consultation on INDs for biologic and drug therapies in children with pediatric rheumatic diseases and consultation on immune-mediated adverse events to biologic therapies and vaccines.  
 Product Reviewer, Division Monoclonal Antibodies (1996 – 2001) and Division of Cellular and Gene Therapies (1993 – 1996), Office of Therapeutics Research and Review (OTRR), CBER, FDA  
 Adjunct Clinical Reviewer, Division of Clinical Trial Design and Analysis, OTRR, CBER, FDA (1994 – 2001), including chair of licensure committee for Etanercept in JRA, IND reviewer or consultant for multiple INDs of biologic therapies for patients with pediatric and adult rheumatic diseases; development of phase 4 studies for juvenile rheumatoid arthritis (JRA); and post-marketing adverse event review for biologic therapies and vaccines  
 Consulting Clinical Reviewer for CBER, Center for Drugs (CDER) and Center for Devices (CDRH), FDA (1994 – 2001): Division of Anti-Inflammatory Drugs, CDER (clinical trials of drugs for JRA, licensure applications and labeling issues for licensure of methotrexate, sulfasalazine and cyclosporine for JRA); vaccine-associated immunologic adverse events; pediatric labeling for blood products; pediatric rheumatic diseases associated with silicone implants  
 Pediatric Clinical Trial Guidance Document (1999): Authored section on adverse event assessment and clinical trial outcome measures.  
 FDA Representative, Advisory Council, Pediatric Rheumatology Collaborative Study Group (1998- 2000)  
 CBER Rheumatology Focus Group, Food and Drug Administration (1996 - 2001)  
 Rheumatology Working Group, Food and Drug Administration (1995 - 2001) - author of Rheumatoid Arthritis and Systemic Lupus Erythematosus Guidance Documents, particularly pediatric policies. Co-chaired and organized workshop on juvenile rheumatoid arthritis (1996)  
 Pediatric Use Working Group, Food and Drug Administration (1995 – 1998). Participated in drafting revisions of 1998 Pediatric Regulation.



## **EDITORIAL AND REVIEW BOARD ACTIVITIES**

Editorial Board, *The Open Rheumatology Journal* (2007 - )

Ad hoc reviewer: *Arthritis and Rheumatism*, *Lancet*, *Arthritis Care and Research*, *Rheumatology*, *Journal of Neuroimmunology*, *Journal of Molecular Diagnostics*, *Journal of Rheumatology*, *Clinical and Experimental Rheumatology*, *Journal of Pediatric Rheumatology*, *Seminars in Arthritis and Rheumatism*, *Scandinavian Journal of Rheumatology*, *Journal of Pediatrics*, *Journal of Clinical Rheumatology*, *Archives of Dermatology*, *Pediatric Dermatology*, *Expert Opinion on Drug Safety*

Grant reviews: The Myositis Association (2002 – present; Chair, Research Review committee 2008), American College of Rheumatology (2008), Prinses Beatrix Fonds (2008), NIAMS RO1 applications (2004), NIAMS PO1 Program Project Grant Applications (2002), Univ Pittsburgh NIAMS Multipurpose Arthritis Center Development and Feasibility grants (2000)

Data Safety Monitoring Board, Ingested Interferon Alpha: Prolongation of Permanence of the “Honeymoon” Phase in Newly Diagnosed Diabetes Mellitus (01-DK-0249) (2002 – 2006)

Consulting reviewer, NIAMS/NIDDK/NIEHS Institutional Review Board (2001 - present)

Advisory Committee, NIH/Hospital for Joint Diseases Registry for Neonatal Lupus (1994 - present)

## **PUBLICATIONS**

### **Publications in Refereed Journals:**

1. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, **L. Rider**, and G. Weissmann. Modes of action of aspirin-like drugs. *Advances in Inflammation Research* 1985; 10: 31-35.
2. Abramson, S., H. Korchak, R. Ludewig, H. Edelson, K. Haines, R.I. Levin, R. Herman, **L. Rider**, S. Kimmel and G. Weissmann. Modes of action of aspirin-like drugs. *Proc. Natl. Acad. Sci.* 1985; 82: 7227-7231.
3. **Rider, L.G.** and J.E. Nidel. Diacylglycerol accumulation and superoxide anion production in stimulated human neutrophils. *J. Biol. Chem.* 1986; 262:5603-5608.
4. **Rider, L.G.**, R.W. Dougherty, and J.E. Nidel. Phorbol diesters and d-octanoylglycerol stimulate accumulation of both diacylglycerols and alkylacylglycerols in human neutrophils. *J. Immunol.* 1988; 140:200-207.
5. **Rider, L.G.**, D.D. Sherry, and S.T. Glass. Neonatal lupus erythematosus simulating transient myasthenia gravis at presentation. *J. Pediatr.* 1991; 118:417-419.
6. **Rider, L.G.**, W.R. Clarke, and J. Rutledge. Clinicopathologic conference: Pulmonary hypertension in a seventeen-year-old boy. *J. Pediatr.* 1992; 120:149-159.
7. **Rider, L.G.**, Buyon, J.P., Rutledge, J., and D.D. Sherry. Treatment of neonatal lupus: Case report and review of the literature. *J. Rheumatol.* 1993; 20:1208-1211.
8. **Rider, L.G.**, M.H. Wener, J. French, D.D. Sherry and P.M. Mendelman. Autoantibody production in Kawasaki syndrome. *Clin Exp Rheumatol.* 1993; 11:445-449.
9. **Rider, L.G.**, N. Raben, L. Miller, and C.L. Jelsema. The cDNAs for two forms of the *lyn* tyrosine kinase are expressed in rat mast cells and human myeloid cells. *Gene.* 1994; 138: 219-222.
10. **Rider, L.G.**, F.W. Miller, I.N. Targoff, D.D. Sherry, E. Samayoa, M. Lindahl, M.H. Wener, L.M. Pachman, and P.H. Plotz. Myositis-specific autoantibodies in children: A broadened spectrum of juvenile myositis. *Arthritis Rheumatism.* 1994; 37:1534-1538.
11. **Rider, L.G.**, P. Thapa, M. DelBecarro, and P.M. Mendelman. Cerebrospinal fluid analysis in children with seizures. *Pediatr. Emerg. Care.* 1995; 11:226-229.
12. **Rider, L.G.\***, N. Hirasawa\*, F. Santini, and M.A. Beaven. Activation of Mitogen Activated Protein Kinase cascade is suppressed by low concentrations of dexamethasone in mast cells. *J. Immunol.* 1996; 157:2374-2380. \* These authors contributed equally.
13. **Rider, L.G.**, B.M. Feldman, M.D. Perez, R.M. Rennebohm, C.B. Lindsley, L.S. Zemel, C.A. Wallace, S.H. Ballinger, S.L. Bowyer, A.M. Reed, M.H. Passo, I.M. Katona, F.W. Miller, and P.A. Lachenbruch, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of Validated Disease Activity and Disease Damage Indices for the Juvenile Idiopathic Inflammatory Myopathies: I. Physician and Parent/Patient Global Assessments. *Arthritis Rheumatism.* 1997; 40: 1976-1983.
14. **Rider, L.G.**, R.C. Gurley, J.P. Pandey, I. Garcia-de la Torre, A.E. Kalovidouris, T.P. O'Hanlon, L.A. Love, R.C.M. Hennekam, L.L. Baumbach, H.E. Neville, C.A. Garcia, J. Klingman, M. Gibbs, M.H.

- Weisman, I.N. Targoff, F.W. Miller. Clinical, serologic and immunogenetic features of familial idiopathic inflammatory myopathy. *Arthritis Rheumatism*. 1998; 41:710-719.
15. Buyon, J.P., R. Hiebert, J. Copel, J. Craft, D. Friedman, M. Katholi, L.A. Lee, T.T. Provost, M. Reichlin, **L. Rider**, A. Rupel, S. Saleeb, W.L. Weston, M.L. Skovron. Autoimmune-associated congenital heart block: Demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. *J. Amer. College Cardiology*. 1998; 31:1658-1666.
  16. Summers, R.M., A.M. Brune, P.L. Choyke, C.K. Chow, N.J. Patronas, F.W. Miller, P.H. White, J.D. Malley, **L.G. Rider**. Juvenile idiopathic inflammatory myopathy: Exercise-induced changes in muscle at short inversion time inversion-recovery MR imaging. *Radiology*. 1998; 209:191-196.
  17. **Rider, L.G.**, E. Shamim, S. Okada, J.P. Pandey, I.N. Targoff, T.P. O'Hanlon, H.A. Kim, Y.S. Lim, H. Han, Y.W. Song, F.W. Miller. Genetic risk and protective factors for idiopathic inflammatory myopathy in Koreans and American Whites: A tale of two loci. *Arthritis Rheumatism*. 1999; 42:1285-1290.
  18. Lovell D.J., CB. Lindsley, RM. Rennebohm, SH. Ballinger, SL. Bowyer, EH Giannini, JE Hicks, JE Levinson, R. Mier, LM Pachman, MH Passo, MD Perez, AM Reed, KN Schickler, M. Smith, LS Zemel, **LG Rider**, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and disease damage indices for the juvenile idiopathic inflammatory myopathies: II. The Childhood Myositis Assessment Scale: A quantitative tool for the evaluation of muscle function. *Arthritis Rheumatism*. 1999; 42:2213-2219.
  19. Laskin, B.L, P. Choyke, G. Keenan, F.W. Miller, **L.G. Rider**. Novel gastrointestinal abnormalities in juvenile dermatomyositis. *J Pediatrics*. 1999; 135:371-374.
  20. **Rider, L.G.\***, C. Artlett\*, C.B. Foster, A. Ahmed, T. Neeman, S. J. Channock, S. Jimenez, F.W. Miller, for the Childhood Myositis Heterogeneity Study Group. IL-1 receptor antagonist (IL-1Ra) VNTR polymorphisms are a possible risk factor for juvenile idiopathic inflammatory myopathies. *Clin Exper. Immunol*. 2000; 121:47-52. \*These authors contributed equally.
  21. Kimball, A.B., R.M. Summers, M. Turner, E. Dugan, J. Hicks, F.W. Miller, and **L.G. Rider**. Magnetic resonance imaging detects occult skin and subcutaneous abnormalities in juvenile dermatomyositis: Implications for diagnosis and therapy. *Arthritis Rheumatism*. 2000; 43:1866-1873.
  22. Wise RP, ME Salive, MM Braun, G Terracciano Mootrey, JF Seward, **L.G. Rider**, PR Krause. Post-licensure safety surveillance for varicella vaccine. *JAMA*. 2000; 284:1271-1279.
  23. Artlett C.M., R. Ramos, S.A. Jimenez, K. Patterson, F.W. Miller, and **L.G. Rider**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. *Lancet*. 2000; 356:2155-2156.
  24. Poitras JM, G.J. Dennis, and **L.G. Rider**. Juvenile dermatomyositis presenting with anasarca. *J Pediatr*. 2000; 138: 942-945.
  25. Huber A, J.E. Hicks, P.A. Lachenbruch, M.D. Perez, L.S. Zemel, R.M. Rennebohm, C.A. Wallace, C.B. Lindsley, M.H. Passo, S.H. Ballinger, S.L. Bowyer, A.M., P.H. White, I.M. Katona, F.W. Miller, **L.G. Rider\***, and B.M. Feldman\*. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. III. The Childhood Health Assessment Questionnaire (CHAQ). *J Rheumatology*. 2001; 28:1106-1111. \*These authors contributed equally.
  26. Artlett CM, FW Miller, **LG Rider**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Persistent maternally derived peripheral microchimerism is associated with the juvenile idiopathic inflammatory myopathies. *Rheumatology*. 2001; 40:1279-1284.
  27. Hicks JE, B. Drinkard, R. Summers, and **L.G. Rider**. Decreased aerobic exercise capacity in children with juvenile dermatomyositis. *Arthritis Rheum (Arthritis Care Research)* 2002; 47: 118-123.
  28. Shamim EA, **LG Rider**, JP Pandey, TP O'Hanlon, LJ Jara, E Samayoa, R Burgos-Vargas, J Vazquez-Mellado, J Alcocer-Varela, M Salazar-Paramo, AG Garcia Kutzbach, JD Malley, IN Targoff, I Garcia de la Torre, and FW Miller. Idiopathic inflammatory myopathy phenotypes and genotypes differ in Mesoamerican Mestizos and North American Caucasians suggesting ethnogeographic influences in the genetics and clinical expression of myositis. *Arthritis Rheum*. 2002; 46: 1885 - 1893.
  29. **Rider LG\***, AS Schiftenbauer\*, M Zito, KL Lim, A Ahmed, LS Zemel, RM Rennebohm, MH Passo, RM Summers, JE Hicks, PA Lachenbruch, MP Heyes, FW Miller, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Neopterin and quinolinic acid are

- surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. *Clin. Chem.* 2002; 48: 1681 – 1688. \*These authors contributed equally.
30. CM Artlett, HB Sawaya, KE Russo-Stieglitz, TP O'Hanlon, AM Lopez, YW Song, FW Miller, and **LG Rider** for the Childhood Myositis Heterogeneity Collaborative Study Group. HLA-DQA1 risk and protective factors for microchimerism vary in different autoimmune diseases and healthy individuals. *Arthritis Rheum.* 2003; 48: 2567-2572.
  31. Isenberg DA, Allen E, Farewell V, Ehrenstein M Hanna M G, Lundberg I E, Oddis C, Pilkington C, Plotz P, Scott D, Venkovsky J, **Rider L**, Miller F., for the International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies: Development and initial validation of myositis activity and damage indices in patients with adult onset disease. *Rheumatology*, 2003; 42: 1 - 7.
  32. BE Drinkard, J Hicks, J Danoff, **LG Rider**. Fitness as a determination of the oxygen uptake/work rate slope in healthy children and children with inflammatory myopathy. 2003; *Can J Appl. Physiol.* 28: 888 - 897.
  33. Okada, S, Weatherhead, E, Targoff, IN, Wesley, R, Miller, FW; **International Myositis Collaborative Study Group**. Global surface ultraviolet radiation intensity may modulate the clinical immunologic expression of autoimmune muscle disease. *Arthritis Rheum.* 2003; 48:2285 - 2293.
  34. RM Rennebohm, K Jones, AM Huber, SH Ballinger, BM Feldman, J Hicks, IM Katona, CB Lindsley, FW Miller, MH Passo, MD Perez, AM Reed, CA Wallace, PH White, LS Zemel, PA Lachenbruch, JR Hayes, and **LG Rider**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Normal scores for nine maneuvers of the Childhood Myositis Assessment Scale (CMAS). *Arthritis Rheum (Arthritis Care Res)*; 2004; 51: 365-370.
  35. AM Huber, BM Feldman, RM Rennebohm, JE Hicks, CB Lindsley, MD Perez, LS Zemel, CA Wallace, SH Ballinger, MH Passo, AM Reed, RM Summers, PH White, IM Katona, FW Miller, PA Lachenbruch, and **LG Rider**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale (CMAS) for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. *Arthritis Rheum*; 2004; 50: 1595-1603.
  36. Siegel K, Hicks JE, Koziol DE, Gerber LH, **Rider LG**. Walking ability and its relationship to lower extremity muscle strength in children with idiopathic inflammatory myopathies. *Arch Phys Med Rehab*; 2004;85: 767-71.
  37. **Rider LG**, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, Lachenbruch PA, Miller FW, for the International Myositis Assessment and Clinical Studies Group. International consensus outcome measures for patients with idiopathic inflammatory myopathies: Preliminary Definitions of Improvement for Adult and Juvenile Myositis. *Arthritis Rheum*; 2004;50: 2281-90.
  38. Chung YL, **Rider LG**, Bell JD, Summers RM, Zemel LS, Rennebohm RM, Passo MH, Hicks J, Miller FW, and Scott DL, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Muscle metabolites, detected in urine by proton spectroscopy, correlate with disease damage in juvenile idiopathic inflammatory myopathies. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2005; 53: 565 - 570.
  39. Oddis CV\*, **Rider LG\***, Reed AM, Ruperto N, Brunner HI, Koneru B, Feldman BM, Giannini EH, Miller FW, for the International Myositis Assessment and Clinical Studies Group (IMACS). International Consensus Guidelines for Therapeutic Trials in the Idiopathic Inflammatory Myopathies. *Arthritis and Rheumatism*. 2005; 52: 2607 – 2715. \*These authors contributed equally.
  40. Mamyrova G, **Rider LG**, Haagenson L, Wong S, Brown KE. Parvovirus B19 and onset of juvenile Dermatomyositis. *JAMA*; 2005. 294: 2170-2171.
  41. O'Hanlon TP, Mercatante Carrick D, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Dreyfuss J, Shamim EA, **Rider LG**, Chanock SJ, Foster CB, Bunch T, Plotz PH, Love LA and Miller FW. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: Distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in Caucasians. 2005. *Medicine*. 2005; 84: 338 – 349.
  42. Nagaraju, K, **Rider LG**, Fan C, Cutting S, Thapliyal R, Mitsak M, Rawat R, Raben N, Patterson K, Grundtman C, Miller FW, Plotz PH, Hoffman E, and Lundberg IE. Endothelial cell activation and neovascularization are prominent in dermatomyositis. 2006. *Journal of Autoimmune Diseases*. 2006: 3:2

43. TP O'Hanlon, D Mercatante Carrick, IN Targoff, FC Arnett, JD Reveille, M Carrington, X Gao, CV Oddis, PA. Morel, JD Malley, K Malley, EA Shamim, **LG Rider**, SJ Chanock, CB Foster, T Bunch, PJ Blackshear, PH Plotz, LA. Love, and FW Miller. HLA-A, -B, -Cw, -DRB1 and -DQA1 Allelic Profiles for the Idiopathic Inflammatory Myopathies: Distinct immunogenetic risk and protective factors distinguish European American patients with different myositis autoantibodies. *Medicine*. 2006; 85: 111- 127.
44. S Pavletic, P Martin, SJ Lee, S Mitchell, D Jacobsohn, EW Cowen, ML Turner, G Akpek, A Gilman, G McDonald, M Schubert, A Berger, P Bross, JW Chien, D Couriel, JP Dunn, J Fall-Dickson, A Farrell, M ED Flowers, H Greinix, S Hirschfeld, L Gerber, S Kim, R Knobler, PA Lachenbruch, FW Miller, B Mittleman, E Papadopoulos, SK Parsons, D Przepiorka, M Robinson, M Ward, B Reeve, **LG Rider**, H Shulman, KR Schultz, D Weisdorf, G Vogelsang. Measuring therapeutic response in Chronic Graft versus Host Disease: NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease: IV. Response Criteria Working Group Report. *Biology of Blood and Marrow Transplantation*. 2006; 12: 252-266.
45. Jain M, Smith M, Cintas H, Koziol D, Wesley R, Harris-Love M, Lovell D, **Rider LG**, Hicks, J. Intra-rater and inter-rater reliability of the 10-point manual muscle test of strength in children with juvenile Idiopathic Inflammatory myopathies. *Physical and Occupational Therapy in Pediatrics*. 2006; 26: 5 – 18.
46. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW\*, **Rider LG\***, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A Novel Autoantibody to a 155 kd Protein is Associated with Dermatomyositis. *Arthritis and Rheumatism*. 2006; 54: 3682- 3689. \*These authors contributed equally.
47. O'Hanlon TP, **Rider LG**, Mamyrova G, Targoff IN, Arnett FC, Reveille JD, Carrington M, Gao X, Oddis CV, Morel PA, Malley JD, Malley K, Shamim EA, Chanock SJ, Foster CB, Bunch T, Reed AM, Love LA, Miller FW. HLA polymorphisms in African Americans with idiopathic inflammatory myopathies: Allelic profiles distinguish patients with different clinical phenotypes and myositis autoantibodies. *Arthritis and Rheumatism*. 2006; 54: 3670 - 3681.
48. Mamyrova G, O'Hanlon TP, Monroe JB, Mercatante Carrick D, Malley JD, Adams S, Reed AM, Shamim EA, James-Newton L, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians. *Arthritis and Rheumatism*. 2006; 54: 3979 – 3987.
49. Mamyrova G, Kleiner DE, James-Newton L, Shaham B, Miller FW, **Rider LG**. Late-Onset Gastrointestinal Pain in Juvenile Dermatomyositis as a Manifestation of Ischemic Ulceration from Chronic Endarteropathy. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2007; 57: 881 - 884.
50. Vegosen LJ, Weinberg CR, O'Hanlon TP, Targoff IN, Miller FW, **Rider LG**. Seasonal Birth Patterns in Subgroups of Myositis Suggest a Role for Early Environmental Exposures in Etiology. *Arthritis and Rheumatism*. 2007; 56: 2719 - 2728.
51. Huber AM, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**. Reliability of the Cutaneous Assessment Tool (CAT) in Juvenile Dermatomyositis. *Rheumatology*. 2007; 46 (10): 1606- 1611.
52. Huber AH, Dugan EM, Lachenbruch PA, Feldman BM, Perez MD, Zemel LS, Lindsley CB, Rennebohm RM, Wallace CA, Passo MH, Reed AM, Bowyer SL, Ballinger SH, Miller FW, **Rider LG**, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group Validation and Clinical Meaning of the Cutaneous Assessment Tool (CAT) in the Juvenile Idiopathic Inflammatory Myopathies. 2008. *Arthritis and Rheumatism (Arthritis Care and Research)*. 59: 214 – 221.
53. Huber AH, Lachenbruch PA, Dugan EM, Miller FW, **Rider LG**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Alternative Scoring of the Cutaneous Assessment Tool (CAT) in Juvenile Dermatomyositis: Results Using an Abbreviated Format. *Arthritis and Rheumatism (Arthritis Care and Research)*. 2008; 59: 352-256.
54. Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Mercatante Carrick D, Sebring N, O'Hanlon TP, Ruiz Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Study Group. Predictors of Acquired Lipodystrophy in Dermatomyositis and a

- Gradient of Severity. *Medicine*. 2008; 87: 70- 86.
55. O'Hanlon TP, **Rider LG**, Schiffenbauer A, Targoff IN, Malley JK, Pandey JP, Miller FW. Immunoglobulin Gene Polymorphisms are Susceptibility Factors in Clinical and Autoantibody Subgroups of the Idiopathic Inflammatory Myopathies. 2008. *Arthritis and Rheumatism*. 58: 3239 – 3246.
  56. Lachenbruch PA, Miller FW, **Rider LG**. On determining the effects of therapy on disease damage in non-randomized studies with multiple treatments: a study of juvenile myositis. 2008. *Communications in Statistics- Theory and Methods*. In press.
  57. Mamyrova G., O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, **Rider LG**, for the Childhood Myositis Heterogeneity Collaborative Study Group. Cytokine Gene Polymorphisms as Risk and Severity Factors for Juvenile Dermatomyositis. *Arthritis and Rheumatism*. 2008. In press.
  58. Harris-Love MO, Shrader JA, Koziol D, Pahlajani N, Jain M, Smith M, Cintas HL, McGarvey CL, James-Newton L, Pokrovnichka A, Moini R, Cabalar I, Lovell DJ, Wesley R, Plotz PH, Miller FW, Hicks JE, **Rider LG**. Distribution and Severity of Weakness Among Polymyositis, Dermatomyositis and Juvenile Dermatomyositis. *Rheumatology*. 2008. In press.

#### **Published Chapters or Articles:**

1. **Rider, L.G.** and F.W. Miller. New perspectives on the idiopathic inflammatory myopathies of childhood. *Curr. Opin. Rheum.* 1994; 6:575-582.
2. **Rider, L.G.** and F.W. Miller. Laboratory evaluation of the inflammatory myopathies. *Clin. Diagn. Lab. Immunol.* 1995; 2:1-9 (peer reviewed).
3. Plotz, P.H., **Rider, L.G.**, Targoff, I.N., Raben, N., O'Hanlon, T.P., and F.W. Miller. Myositis: Immunologic contributions to understanding causes, pathogenesis and therapy. *Ann. Intern. Med.* 1995; 122: 714-724 (peer reviewed).
4. **Rider, L.G.** Assessment of disease activity and its sequelae in children and adults with myositis. *Current Opin Rheumatology*. 1996; 8:495-506.
5. **Rider, L.G.** and F.W. Miller. Classification and treatment of juvenile idiopathic inflammatory myopathies. *Rheum. Dis. Clin. N. Amer.* 1997; 23:619-655.
6. **Rider, L.G.** and I.N. Targoff. Single organ systems and autoimmunity: Muscle Diseases. *Textbook of Autoimmune Diseases*, ed. R.G. Lahita, N. Chiorazzi, W.H. Reeves. Lipincott- Raven, Philadelphia, PA. 2000; pg 429 – 474.
7. **Rider, L.G.** and F.W. Miller. Idiopathic inflammatory muscle disease: Clinical aspects. *Bailliere's Best Practice and Research: Clin. Rheumatol.* 2000; 14:37 - 54.
8. Shamim E, **L.G. Rider**, and F.W. Miller. Genetic risk factors for the idiopathic inflammatory myopathies. *Current Opinion Rheumatol.* 2000; 12:482-91.
9. Miller FW\*, **LG Rider\***, YL Chung, R Cooper, K Danko, V Farewell, I Lundberg, C Morrison, L Oakley, I Oakley, C Pilkington, J Vencovsky, K Vincent, DL Scott, DA Isenberg, for the International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. *Rheumatology*. 2001; 40: 1262-1273. \*These authors contributed equally.
10. Barron KS, C Wallace, A Woolfrey, RM Laxer, M Horwitz, J Siegel, L Filipovich, N Wulffraat, M Passo, and **LG Rider**. Report on the National Institutes of Health workshop on autologous stem cell transplantation for pediatric rheumatic diseases. *J Rheumatol.* 2001; 28:2337-58.
11. **Rider, L.G.** Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. *Rheum. Disease Clin. N. Amer.* 2002; 28: 935 – 977.
12. **Rider, L.G.** Juvenile dermatomyositis (chapter 12.10). *Rudolph's Pediatrics*, 21<sup>st</sup> edition. CD Rudolph, AM Rudolph, eds. McGraw-Hill, NY. 2003; 853 – 856.
13. **Rider LG**, EH Giannini, M Harris-Love, G Joe, D Isenberg, C Pilkington, PA Lachenbruch, FW Miller, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Workshop report: Defining clinical improvement in adult and juvenile myositis. *J Rheumatol.* 2003; 30: 603-617.

14. **Rider, LG.** Calcinosis in Juvenile Dermatomyositis: Pathogenesis and Current Therapies. *Pediatr Rheum On Line Jour* 2003 1;2:  
<http://www.pedrheumononlinejournal.org/April/calinosi.html>. (peer reviewed)
15. N Ruperto, A Ravelli, KJ Murray, DJ Lovell, B Andersson-Gare, BM Feldman, S Garay, W Kuis, C Machado, L Pachman, AM Prieur, **LG Rider**, E Silverman, E Tsitsami, P Woo, EH Giannini, A Martini, for the PRINTO and the PRCSSG. Workshop report: International consensus for disease activity and disease damage core sets of outcome measures for juvenile systemic lupus erythematosus and juvenile dermatomyositis. *Rheumatology*, 2003;42: 1-8. (peer reviewed)
16. **Rider LG**, Pachman LM, Miller FW, Bollard H. Introduction. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association, Washington DC. Page 1 -8.
17. **Rider LG** and FW Miller. What is Juvenile Myositis? Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association, Washington DC. Pages 9 - 22.
18. **Rider LG**, Pilkington C, Malleson P. Possible Medicines During the Course. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 153 - 172
19. **Rider LG**, Pilkington C, Ruperto N, Isenberg, D. Charting Your Child's Progress. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 127- 138.
20. **Rider LG** and Pachman LM. Calcinosis. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. Pages 231 - 240.
21. Rennebohm R, Feldman B, Huber A, Spencer C, Sundel R, and **Rider LG**. The clinical course and outcome of juvenile myositis. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007, The Myositis Association, Washington DC. pages 341 - 350.
22. Lachenbruch PA, Miller FW, **Rider LG**. Developing international consensus on measures of improvement for myositis. *Statistical Methods in Medical Research*, 2007, 1: 51 - 64. (peer reviewed)
23. **Rider LG**. The heterogeneity of juvenile myositis. *Autoimmunity Reviews*. 2007; 6: 241-247.
24. Mellins ED and **Rider LG**. Clinical research networks: a step towards evidence-based practice in pediatric rheumatology (editorial). *Nature Clinical Practice Rheumatology*. 2007; 3: 59.
25. **Rider LG** and Miller FW. Pathology and pathogenesis of idiopathic inflammatory myopathies. *Primer on the Rheumatic Diseases*. Ed Klippel JH, Stone JH, Crofford LJ, White PH. Springer. 2007. Pg 368 - 374.
26. Yao L and **Rider LG**. Chapter 54: Idiopathic inflammatory myopathy. *Imaging of the Musculoskeletal System*, 1<sup>st</sup> Edition. TL Pope, HL Bloem, J Beltran, WB Morrison, DJ Wilson, editors. Elsevier. Philadelphia, PA. 2008. Pages 1171 – 1179.
27. Feldman BM, **Rider LG**, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. *Lancet*. 2008; 371: 2201 – 2212. (peer reviewed)
28. **Rider LG**. Juvenile dermatomyositis (chapter 232). *Rudolph's Pediatrics*. *Rudolph's Pediatrics*, 22<sup>nd</sup> edition. AM Rudolph, C Rudolph, L First, G Lister, AA Gershon, eds. McGraw-Hill, NY. 2008. In press.
28. **Rider LG**, Leschek EW. Commentary on the recent article by Simon et al. on human growth hormone treatment for patients with juvenile idiopathic arthritis. *Nature Clinical Practice Rheumatology*. 2008; 4: 395. (peer reviewed)
29. **Rider LG**. Outcomes and Assessment. *Inflammatory Muscle Disease*. Ed Lawrence Kagen. Springer Humana. 2008. In press.
30. Reed AM, Pilkington C, Feldman BM, Pachman LM, **Rider LG**. Juvenile dermatomyositis. In *Rheumatology Clinical Pearls and Myths*. John Stone, Ed. Springer. 2008. In press.

**Books:**

**Rider LG**, Pachman LM, Miller FW and Bollar H, editors. Myositis and You: A Guide to Juvenile Dermatomyositis for Patients, Families and Health Care Providers. 2007. The Myositis Association. Washington DC.

**Letters:**

1. **Rider LG**, PM Mendelman, J French, and DD Sherry. Group A streptococcal infection and Kawasaki syndrome. *Lancet* 1991; 337:1100-1101.
2. Miller, FW, **Rider LG**, Plotz PH, Isenberg DA, Oddis CV. Diagnostic criteria for polymyositis and dermatomyositis. *Lancet* 2003; 362:1762-1763.
3. Miller FW, **Rider LG**, Plotz PH, Rutkove SB, Pestronk A, Wortmann RL, Lundberg IE, Argov Z, Isenberg DA, Lacomis D, Oddis CV. Polymyositis: An overdiagnosed entity. *Neurology*. 2004; 63:402.
4. Huber AM, Miller FW, **Rider LG**. Childhood Myositis Assessment Scale and muscle strength testing in patients with juvenile dermatomyositis: comment on the article by Huber et al – Reply. *Arthritis and Rheumatism* 2005; 52: 368-369.
5. **Rider LG**, Miller FW, Lachenbruch PA, Isenberg D. Applicability of the Paediatric Rheumatology International Organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et. al. 2008. *Arthritis and Rheumatism (Arthritis Care and Research)*. In press.

**Selected Published Abstracts (75 total):**

1. **Rider LG**, CA Wallace, DD Sherry, and FW Miller. Autoimmune diseases in family members of children with idiopathic inflammatory myopathies. *Arthritis Rheumatism*. 1994; 37(suppl): S403.
2. **Rider LG**, IN Targoff, RL Leff, KJ Bloch, BL Gruber, CV Oddis, DD Sherry, and FW Miller. Association of autoantibodies to the U5-ribonucleoprotein (U5-RNP) with idiopathic inflammatory myopathy. *Arthritis Rheumatism*. 1994; 37(suppl): S242.
3. **Rider LG**, IN Targoff, ES Taylor-Albert, LI Ray, R Pappu, JC Jacobs, LM Pachman, FW Miller. Anti-Jo1 autoantibodies define a clinically homogenous subset of childhood idiopathic inflammatory myopathy. *Arthritis Rheum*. 1995; 38 (suppl): S362.
4. **Rider LG**, S Okada, DD Sherry, CA Wallace, LS Zemel, JC Jacobs, CB Lindsley, RF Rivas-Chacon, S Sheehy, SA Vogelgesang, JJ Miller, S Stein-Yandashevskaya, DA Person, JC Olson, KL Madson, IM Katona, BH Athreya, PH White, RM Rennebohm, FW Miller, for the Childhood Myositis Heterogeneity Study Group. Epidemiologic features and environmental exposures associated with illness onset in juvenile idiopathic inflammatory myopathy. *Arthritis Rheum*. 1995; 38 (suppl): S362.
5. **Rider LG**, S Okada, DD Sherry, CA Wallace, LS Zemel, CB Lindsley, RM Rennebohm, RS Rivas-Chacon, S Sheehy, SA Vogelgesang, DA Person, JC Olson, JJ Miller, S Stein-Yandashevskaya, KL Madson, IM Katona, BH Athreya, PH White, JC Jacobs, FW Miller, for the Childhood Myositis Heterogeneity Study Group. Presentations and disease courses of juvenile idiopathic inflammatory myopathy. *Arthr. Rheum*. 1995; 38 (suppl): S362.
6. **Rider L**, P Lachenbruch, R Rennebohm, C Wallace, L Zemel, C Lindsley, B Feldman, S Bowyer, M Perez, A Reed, M Passo, S Ballinger, J Levinson, D Lovell, S Vogelgesang, W James, F Miller, E Dugan, for the Juvenile Dermatomyositis Disease Activity Study Group. Identifying skin lesions in dermatomyositis: Inter-rater reliability of a new cutaneous assessment tool. *Arthritis Rheum*. 1995; 38 (suppl): S168.
7. **Rider L**, K Prasad, B Feldman, M Perez, C Lindsley, L Zemel, R Rennebohm, S Ballinger, S Bowyer, S Okada, J Miller, A Rosenberg, A Reed, C Wallace, R Sundel, M Passo, I Katona, P White, L Pachman, P Lachenbruch, and F Miller, for the JDM Disease Activity Collaborative Study Group. Relationships among laboratory tests and global disease activity assessments in juvenile dermatomyositis. *Arthritis Rheum*. 1996; 39 (suppl): S191.
8. **Rider L**, B Sonies, D Sapper, B Solomon, I Katona, S George, C Lindsley, P White, and F Miller. Swallowing and oral motor abnormalities are frequent in juvenile idiopathic inflammatory myopathy. *Arthritis Rheum*. 1996; 39 (suppl): S191.
9. **Rider L**, S Okada, A Reed, E Zachariah, E Shamim, D Sherry, J Jacobs, M Perez, C Wallace, J

- Olson, C Lindsley, L Zemel, R Rennebohm, S Vogelgesang, D Person, J Bohnsack, K Madson, R Rivas-Chacon, R Sundel, J Yee, L Ray, I Katona, B Athreya, P White, J Pandey, and F Miller, for the Childhood Myositis Heterogeneity Study Group. Immunogenetic risk factors for juvenile idiopathic inflammatory myopathy. *Arthritis Rheum.* 1996; 39 (suppl): S309.
10. **Rider L**, J Pandey, D Sherry, C Wallace, D Person, J Olson, J Jacobs, I Targoff, and F Miller, for the Childhood Myositis Heterogeneity Study Group. Polymorphisms in cytokine genes are associated with juvenile idiopathic inflammatory myopathy. *Arthritis Rheum.* 1996; 39 (suppl): S190.
  11. Okada S, **LG Rider**, K Prasad, I Garcia-De La Torre, R Burgos-Vargas, J Vazquez-Mellado, J Alcocer-Varela, L Guzman, I Pande, PO Behan, WMH Behan, I Hausmanowa-Petrusewica, S Jablonska, YW Song, LA Love, PH Plotz, IN Targoff, and FW Miller, in cooperation with the International Myositis Collaborative Study Group. Latitudinal gradients in the relative prevalence of dermatomyositis and its associated autoantibody, anti-Mi-2, in idiopathic inflammatory myopathy. *Arthritis Rheum.* 1996; 39 (suppl): S101.
  12. Rother KI, **LG Rider**, RV Considine, MI New, SI Taylor. Leptin concentrations and endocrine abnormalities in patients with lipodystrophy and lipoatrophic diabetes. *Hormone Research.* 1997; 48 (suppl. 2): 194 (abstract 858).
  13. **Rider L**, A Ahmed, L Beausang, L Zemel, R Rennebohm, L Pachman, M Passo, R Sundel, J Miller, A Rosenberg, C Wallace, S Ballinger, S Bowyer, A Reed, P White, P Lachenbruch, F Miller for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Elevations of interleukin-1 receptor antagonist (IL1RA), sTNFR, sIL2R, and IL-10 in juvenile idiopathic inflammatory myopathies suggest a role for monocyte/macrophage and B lymphocyte activation. *Arthritis Rheum.* 1998; 41(suppl.): S264.
  14. Shamim E, **L Rider**, M Perez, G Cawkwell, R Wise and F Miller. Demographic and clinical features of patients who develop myositis following immunization. *Arthritis Rheum.* 1998; 41 (suppl.):S204.
  15. Chung Y, **L Rider**, J Bell, L Zemel, R Rennebohm, M Passo, P White, S George, I Katona, F Miller, D Scott, for the JDM Disease Activity Collaborative Study Group. Muscle metabolites detected in urine reflect disease activity in juvenile dermatomyositis. *Arthritis Rheum.* 1999; 42 (suppl.): S156.
  16. Feldman BM, **LG Rider**, L Dugan, FW Miller, and R Schneider, for the Juvenile Myositis Collaborative Study Group. Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies. *Arthritis Rheum.* 1999; 42 (suppl.): S664.
  17. Hicks J, R Wesley, D Koziol, M Smith, M Jain, H Cintas, D Lovell, B Feldman, S Bowyer, S Ballinger, C Lindsley, L Pachman, F Miller, **L Rider**, for the JDM Disease Activity Collaborative Study Group. Validation of manual muscle testing in the assessment of juvenile dermatomyositis. *Arthritis Rheum.* 2000; 43 (suppl.): S194.
  18. Hicks J, R Wesley, D Koziol, M Smith, M Jain, H Cintas, D Lovell, B Feldman, S Bowyer, S Ballinger, C Lindsley, L Pachman, F Miller, **L Rider**, for the JDM Disease Activity Collaborative Study Group. Preliminary validation of abbreviated manual muscle testing in the assessment of juvenile dermatomyositis. *Arthritis Rheum.* 2000; 43 (suppl.): S195.
  19. Targoff I, E Shamim, D Sherry, C Wallace, H Haftel, F Miller, **L Rider**, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel dermatomyositis-associated autoantibody directed against a 155 kd protein. *Arthritis Rheum.* 2000; 43 (suppl.): S175.
  20. Jain M, M Smith, J Danoff, **L Rider**, J Hicks. Comparison of the Pediatric Evaluation Disability Inventory (PEDI) and the Childhood Health Assessment Questionnaire (CHAQ) in children with juvenile dermatomyositis. *Arthritis Rheum.* 2000; 43 (suppl.): S180.
  21. Hicks J, R Wesley, D Koziol, B Feldman, K Whitney, E Adams, M Villalba, M Jain, C Lindsley, S Wright, L Pachman, P Plotz, E Giannini, F Miller, **L Rider**. Consensus and economic advantages in use of abbreviated manual muscle testing in the assessment of idiopathic inflammatory myopathies. *Arthritis Rheum.* 2001; 44 (suppl.): S352.
  22. **L Rider**, B Sonies, B Solomon, B Feldman, M Perez, L Zemel, R Rennebohm, C Wallace, C Lindsley, S Bowyer, S Ballinger, A Reed, P White, I Katona, J Hicks, P Lachenbruch, F Miller, for the JDM Disease Activity Collaborative Study Group. Voice abnormalities are frequent in juvenile idiopathic inflammatory myopathies and correlate with muscle strength and function. *Arthritis Rheum.* 2001; 44 (suppl.): S293.
  23. **L Rider**, M Ruiz-Hidalgo, J Laborda, S Bauer, G Cawkwell, M Knee, C Lindsley, B Athreya, H Haftel,



- R Rennebohm, D Sherry, P White, I Targoff, F Miller, E Arioglu, for the Childhood Myositis Heterogeneity Collaborative Study. Lipodystrophy in juvenile dermatomyositis is associated with calcinosis, but not with adipocyte differentiation factor *dlk* levels. *Arthritis Rheum.* 2001; 44 (suppl.): S264.
24. Pilkington C, K Murray, D Isenberg, V Farewell, J Davidson, B Feldman, A Ravelli, R Rennebohm, C Ryder, E Allen, F Miller, **L Rider**. Development of disease activity and damage indices for myositis: Initial testing of four tools in juvenile dermatomyositis. *Arthritis Rheum.* 2001; 44 (suppl.): S294.
  25. **Rider L**, A Schiffenbauer, M Villalba, E Adams, G Joe, M Harris-Love, L James-Newton, J Hicks, C Pilkington, D Isenberg, P Lachenbruch, F Miller, and the JDM Disease Activity Collaborative Study Group. Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures. *Arthritis Rheum.* 2002; 46 (suppl.): S612 - 613.
  26. C Pilkington, D Isenberg, V Farewell, J Davidson, B Feldman, A Ravelli, R Rennebohm, C Ryder, E Allen, F Miller and **L Rider**. Development of disease damage indices for juvenile myositis: Preliminary reliability and content validity. *Arthritis Rheum.* 2002; 46 (suppl.): S308.
  27. EM Dugan, FW Miller, **LG Rider** for the JDM Disease Activity Collaborative Study Group. The Myositis Cutaneous Assessment Tool (MCAT): A new approach to the assessment of cutaneous disease activity and damage in Adult and Juvenile Dermatomyositis. *Ann Rheum Dis.* 2003; 62 (suppl): 31-32.
  28. **L Rider**, A Reed, L James-Newton, B Feldman, A Ravelli, I Cabalar, M Villalba, R Rennebohm, L Pachman, C Lindsley, E Adams, M Passo, L Zemel, C Wallace, P White, B Myones, P Plotz, D Isenberg, P Lachenbruch, F Miller, for the IMACS Group. Assessing the Extent and Severity of Damage in Adult and Juvenile Myositis (IIM) by the Myositis Damage Index (MDI). *Arthritis Rheum.* 2003; 48 (suppl.): S307.
  29. C Oddis, F Miller, B Koneru, B Feldman, E Giannini, H Brunner, N Ruperto, A Reed, **L Rider**, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Development of Consensus Criteria for the Conduct of Clinical Trials in Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM). *Arthritis Rheum.* 2003; 48 (suppl.): S308.
  30. K Nagaraju, R Thapayilal, C Neill-Marshall, C Danning, R Rawat, **L Rider**, F Miller and P Plotz. Increased neovascularization and dendritic cell presence in close proximity to endothelial cells in myositis biopsies. *Arthritis Rheum.* 2003 48 (suppl): S435.
  31. G Mamyrova, D Kleiner, A Bingham, E Cochran, L Imundo, C Lindsley, J Morris, R Rivas-Chacon, L Jung, A Baer, F Miller, E Oral, **L Rider**, for the Childhood Myositis Heterogeneity Study Group. Non-Alcoholic Steatohepatitis (NASH) is a Frequent Complication of Acquired Lipodystrophy Associated with Juvenile Dermatomyositis. *Arthritis Rheum.* 2003 48 (suppl): S514.
  32. G Mamyrova, I Targoff, C Lindsley, C Wallace, H Haftel, E Oral, G Cawkwell, T Finkel, H Gewanter, D Goldsmith, G Higgins, O Jones, I Katona, M Knee, A Lawton, C Morishimo, C Parker, M Passo, M Perez, D Person, R Rivas-Chacon, D Sherry, I Szer, Tutimoto, L Zemel, F Miller, **L Rider**, for the Childhood Myositis Heterogeneity Study Group, NIEHS, NIH, DHHS, Bethesda, MD. Distinguishing Clinical Features of JDM Associated with a Myositis-Associated Autoantibody (MAA) Directed Against a 155 kDa Protein. *Arthritis Rheum.* 2003 48 (suppl): S514.
  33. N Ruperto, P Woo, R Cuttica, E Cortis, M Alessio, O Porras, S Garay, F Sztajn bok, H Ozdogan, N Wulffraat, F Kanakoudi, A Quezada, V Gerloni, F Falcini, H Venning, G Susic, AM Prieur, V Ferriani, M Hofer, C DeCunto, **L Rider**, L Trail, A Pistorio, EH Giannini, A Martini, Pediatric Rheumatology International Trials Organization. The validated PRINTO core set and definition of improvement for juvenile myositis. *Arthritis Rheum.* 2004; 50 (suppl): S534.
  34. G Mamyrova, L Haagenson, S Wong, M Perez, D Sherry, L Imundo, C Wallace, FW Miller, **LG Rider**, KE Brown. Parvovirus B19 is not associated with the onset of juvenile Dermatomyositis. *Arthritis Rheum.* 2004; 50 (suppl): S103.
  35. G Mamyrova, T O'Hanlon, A Reed, L James-Newton, D Sherry, C Wallace, C Lindsley, M Perez, M Henrickson, R Rivas-Chacon, G Higgins, I Katona, J Olson, FW Miller, **LG Rider**. HLA DRB1\*0301 and DQA1\*0501 are independent and synergistic genetic risk factors for juvenile dermatomyositis. *Arthritis Rheum.* 2004; 50 (suppl): S668.

36. L Vegosen, C Weinberg, T O'Hanlon, I Targoff, F Miller and **L Rider**. Seasonal subgroups in subgroups of juvenile myositis suggest a role for gestational factors in etiology. May 2005. Pediatric Academic Societies meeting. Washington, DC. (Platform presentation)
37. **L Rider**, M Villalba, E Adams, G Joe, M Harris-Love, S Hill, L James-Newton, J Hicks, P Plotz, P Lachenbruch, F Miller, and the JDM Disease Activity Collaborative Study Group. Validity of the Myositis Disease Activity Assessment Tool (MDAAT) for Assessing Extra-muscular Disease Activity in Adult and Juvenile Idiopathic Inflammatory Myopathies (IIM). *Arthritis Rheum*. 2005; 52 (suppl): S315.
38. A Huber, E Dugan, P Lachenbruch, B M Feldman, M Perez, L Zemel, C Lindsley, R Rennebohm, C Wallace, M Passo, A M Reed, S Bowyer, S Ballinger, F Miller, **L Rider**. Reliability of the Cutaneous Assessment Tool (CAT) in Juvenile Dermatomyositis (JDM). *Arthritis Rheum*. 2005; 52 (suppl): S 314-S315.
39. L Vegosen, C Weinberg, T O'Hanlon, I Targoff, B Koneru, G Mamyrova, F Miller, **L Rider**, and the Childhood Myositis Heterogeneity Study Group. Seasonal Birth Patterns in Subgroups of Myositis Suggest a Role for Perinatal Environmental Factors in Etiology. *Arthritis Rheum*. 2005; 52 (suppl): S228.
40. G Mamyrova, D Carrick, T O'Hanlon, J Malley, A Reed, D Sherry, C Wallace, L James-Newton, L Zemel, M Perez, C Lindsley, F Miller, **L Rider**, and the Childhood Myositis Heterogeneity Study Group. Relative Importance of Immunogenetic Risk and Protective Factors for the Development of Juvenile Dermatomyositis (JDM) in European American (EA) Patients. *Arthritis Rheum*. 2005; 52 (suppl): S308-S309.
41. G Mamyrova, T O'Hanlon, D Carrick, J Malley, F Miller, **L Rider**, and the Childhood Myositis Heterogeneity Study Group. DRB1\*0301 and the Second Hypervariable Region DRB1 Motif, <sup>70</sup>QKRGR<sup>74</sup> are HLA Risk Factors for Dermatomyositis (DM) in African-American (AA) Patients. *Arthritis Rheum*. 2005; 52 (suppl): S308.
42. G. Mamyrova, L. Sillers, T. O'Hanlon, J. Pandey, C. Parks, J. Malley, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, G. S. Cooper, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Interleukin-1 and Tumor Necrosis Factor Alpha Polymorphisms are Risk and Protective Factors for Juvenile Dermatomyositis (JDM). *Arthritis and Rheumatism*. 2006; 54 (suppl): S831.
43. G. Mamyrova, L. Sillers, T. O'Hanlon, J. Pandey, J. Malley, S. Adams, L. James-Newton, C. Wallace, D. Sherry, L. Imundo, C. Lindsley, K. Madson, M. Perez, F. Miller, L. Rider, and the Childhood Myositis Heterogeneity Study Group. Cytokine and HLA Alleles Modulate Disease Severity in Juvenile Dermatomyositis (JDM). *Arthritis and Rheumatism*. 2006; 54 (suppl): S692-693.
44. A Huber, E Dugan, P Lachenbruch, BM Feldman, M Perez, L Zemel, C Lindsley, R Rennebohm, C Wallace, M Passo, AM Reed, S Bowyer, S Ballinger, F Miller, L Rider Construct and Content Validity, Responsiveness and Clinical Meaning of the Cutaneous Assessment Tool (CAT) in Juvenile Idiopathic Inflammatory Myopathy (IIM). *Arthritis and Rheumatism*. 2006; 54 (suppl): S804-805.
45. A Bingham, G Mamyrova, E Cochran, E Oral, L James-Newton, A Pokrovnicka, L Imundo, F Miller, L Rider, A Premkumar. MRI Characterization of Regional Fat Loss in Patients with Lipodystrophy Complicating Dermatomyositis. *Arthritis and Rheumatism*. 2006; 54 (suppl): S169-170.
46. K. Coyle, K. Rother, M. Weise, A. Ahmed, F. Miller, **L. Rider**. Abnormal Glucose and Lipid Metabolism and Impaired Growth and Development are Frequent Endocrine Findings in Juvenile Myositis. *Arthritis and Rheumatism* 2007; 55 (suppl): S649-50.
47. Huber AM, Dugan EM, Lachenbruch PA, Miller FW, **Rider LG**, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Towards an Abbreviated Cutaneous Assessment Tool (CAT). *Arthritis and Rheumatism* 2007; 55 (suppl): S651.
48. G. Mamyrova, CA. Bingham, EA Oral, K. Rother, E. Cochran, N. Sebring, J. Pandey, L. James-Newton, T. O'Hanlon, I. Targoff, F. Miller, **L. Rider**. Clinical and Metabolic Characteristics of Acquired Lipodystrophy in Juvenile Dermatomyositis *Arthritis and Rheumatism* 2007; 55 (suppl): S145.
49. **L Rider**, P Lachenbruch, L James-Newton, I Cabalar, B Feldman, A Ravelli, B Myones, R Rennebohm, L Pachman, M Villalba, E Adams, C Lindsley, C Wallace, L Zemel, A Reed, F Miller, for the IMACS Group Predictors of Calcinosis in Juvenile and Adult Myositis. *Arthritis and Rheumatism*. 2008; 58 (S): **S230**.
50. **L. Rider**, P. Lachenbruch, L. James-Newton, I. Cabalar, B.M. Feldman, A. Ravelli, B. Myones, R. Rennebohm, L. Pachman, M. Villalba, E. Adams, C. Lindsley, C. Wallace, S. Ballinger, L. Zemel, A.

Reed, F. Miller, IMACS Group Effects of Treatment on Disease Damage in Juvenile and Adult Myositis . Arthritis and Rheumatism , 2008; 58S, S229.

### **Government Publications:**

Guidance for Industry: Clinical Development Programs of Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis. Food and Drug Administration February 1999.

<http://www.fda.gov/cder/guidance/1208fnl.htm>.

### **Internet Sites:**

<https://dir-apps.niehs.nih.gov/imacs/home.htm>

### **INVITED LECTURES AND SELECTED PRESENTATIONS**

“Clinical Databases: Setup and Maintenance for Clinical Data Sharing”, NIAMS Conference on SAPHO/Bechet’s, Bethesda, MD, September 4, 2008

“Adult and Juvenile Myositis”, George Washington University Rheumatology lecture series, July 18, 2008  
Participant, Career as a Pediatric Rheumatologist and Clinical Researcher, Lucy Barnsley Elementary School Career Day, Rockville, MD, May 2007 and May 30, 2008

“Components and Predictors of Damage in Juvenile Myositis Using the Myositis Damage Index”, American College of Rheumatology Pediatric Rheumatology Meeting, Keystone, CO, March 4, 2008

“Ask the Expert: Online Chat on Juvenile Myositis”, The Myositis Association, February 22, 2008

Invited Participant, CARRA Consensus Conference to Develop Treatment Protocols for Juvenile Dermatomyositis, November 30 – December 2, 2007, Toronto, Canada

Department of Pediatrics Grand Rounds, Children’s Memorial Hospital, Northwestern University School of Medicine, “Juvenile Myositis: A Research Perspective”, Chicago, IL, November 16, 2007

“Rheumatic Disease Update: Adult and Juvenile Dermatomyositis/Polymyositis”, American Rheumatology Health Professionals, Boston, MA, November 10, 2007

Cure JM Foundation Educational Forum and Panel Discussion, “Juvenile Myositis: Assessing Outcomes and Potential New Therapies”, Arlington, VA, October 27, 2007

Department of Pediatrics Grand Rounds, Georgetown University School of Medicine, “Juvenile Myositis: A Clinical Update”, Washington DC, May 11, 2007

Rheumatology Grand Rounds, George Washington University School of Medicine, “Juvenile Myositis”, Washington DC, March 29, 2007

Clinical Immunology Society School for Autoimmune Diseases, “Immunogenetic and Environmental Risk Factors for Juvenile Myositis”. Faculty, March 14 -18, 2007, Santa Fe, New Mexico.

“IMACS Clinical Data Repository” and Chair, IMACS/JDM Working Group Breakfast Meeting, November 14, 2006, Washington, DC

American College of Rheumatology, Pediatric Study Section, “Immunogenetic and Environmental Risk Factors for Juvenile Myositis”, Washington DC, November 13, 2006

Rheumatology Grand Rounds, Georgetown University School of Medicine, “Juvenile Myositis”, Washington DC, October 25, 2006

Ann Hengel Lecture in Pediatric Rheumatology. “Juvenile Dermatomyositis” Medical College of Wisconsin, Milwaukee, Wisconsin. April 28, 2006.

Clinical Immunology Society School for Autoimmune Diseases, “Juvenile Myositis”. Faculty, March 15 - 18, 2006, Santa Fe, New Mexico.

Invited Alumni Panelist, “Medicine and Research”, Duke University Career Week, January 28, 2006, Durham, NC.

American Academy of Pediatrics Workshop, “Juvenile Dermatomyositis Dilemmas: A Case of Flare Following Remission”. November 15, 2005, San Diego, CA.

Meeting co-organizer and presentation of “IMACS Internet Site” and “IMACS Outcomes Repository”, November 13, 2005, San Diego, CA.

Rituximab in Myositis Investigator’s Meeting, “Core Set Measures, including the MMT8, and the Definition of Improvement”, and “Rituximab in Myositis Study Protocol” October 29, 2005 and February 6, 2006, Bethesda, MD.

The Myositis Association Annual Conference. Medical Panel: “TMA’s Research Program and Funded

Research on Juvenile Myositis” and Workshop on “Juvenile Myositis”, October 8, 2005, Cleveland, OH.

American Juvenile Arthritis Organization National Conference. “Juvenile Dermatomyositis” Workshop and Roundtable Discussion, July 29, 2005, Providence, RI.

Rheumatology Grand Rounds, University of Pittsburgh, Pittsburgh, PA. November 12, 2004.

“Classification of Juvenile Myositis”, Working Group meeting on the Classification of Idiopathic Inflammatory Myopathies, October 26, 2004, Bethesda, MD; Meeting co-organizer for Working Committee meeting, November 11, 2005, Dulles Airport, VA.

“IMACS Internet Site and Clinical Data Repository” and Chair, IMACS Breakfast Meeting, October 18, 2004, San Antonio, TX

“Juvenile Myositis Handbook”, The Myositis Association, Conference on Juvenile Myositis, May 9, 2004, Bethesda, MD.

Rheumatology Grand Rounds, Hospital for Special Surgery, Cornell Medical College, NY, NY, February 11, 2004

Invited Alumni Panelist, Duke University Career Week, Durham, NC, January 31, 2004 (sessions on Science and Research, Women and Leadership).

“Meet the Professor: Juvenile Dermatomyositis”, American College of Rheumatology meeting, November 12/13, 2001, San Francisco, CA; October 26/27, 2002, New Orleans, LA; October 27-29, 2003; Orlando, FL; October 25/27, 2003, Orlando, FL.

American College of Rheumatology meeting, October 28, 2003, Orlando, FL: Presentation of paper, “Preliminary Definitions of Improvement for Juvenile Myositis”

Meeting Co-Organizer and Presentation of several papers (“Summary of IMACS Definitions of Improvement”, “Future Plans for IMACS” Workshop”), IMACS Meeting, October 27, 2003, Orlando, FL.

Invited Participant and Speaker, Pediatric Rheumatology International Trials Organization (PRINTO) International Consensus Conference on Defining Improvement in Juvenile Dermatomyositis. “IMACS Preliminary Definitions of Improvement for Juvenile and Adult Myositis”. September 29 – 30, 2003, Camogli, Italy.

European League Against Rheumatism (EULAR) meeting, “Preliminary Definitions of Improvement for Adult and Juvenile Myositis” and moderated session on Difficult Cases of Myositis/Myopathies, June 20, 2003, Lisbon, Portugal

Invited Participant, Consensus Conference to Develop Criteria for Inactive Disease in Juvenile Rheumatoid Arthritis, May 3- 4, 2003 Marco Island, FL

Schlager Family Visiting Professor Lectureship in Juvenile Dermatomyositis April 30, 2003, Children’s Hospital, Boston, MA: “Juvenile Idiopathic Inflammatory Myopathies: Lessons from the Children”.

Rheumatology Grand Rounds, Brigham and Women’s Hospital: Evaluation and Treatment of the Juvenile Idiopathic Inflammatory Myopathies, April 29, 2003, Boston, MA.

American Academy of Pediatrics Pediatric Rheumatology 2003: Park City and Beyond: General Session, “Preliminary Definitions of Improvement for Juvenile and Adult Myositis” (March 26, 2003); Meet the Expert, “Juvenile Dermatomyositis” (March 23, 2003); Concurrent Session, “The Development of Outcome Measures for Juvenile Dermatomyositis” (March 23, 2003), Snowmass, CO.

American College of Rheumatology meeting, Clinical Symposium, “Treatment of Refractory Juvenile Dermatomyositis”, October 26, 2002, New Orleans, LA.

American College of Rheumatology meeting, October 29, 2002, New Orleans, LA: Presentation of 2 papers, “Extra muscular disease activity is frequent in adult and juvenile idiopathic inflammatory myopathies (IIM) and does not correlate with other myositis activity measures” and “Defining clinically relevant change in core set activity measures for adult and juvenile idiopathic inflammatory myopathies”

Meeting Co-Organizer and Presentation of several papers (“Summary of the First Workshop”, “Top Candidate Definitions of Improvement for Adult and Juvenile Myositis”, “Clinical Trial Design Issues”, “Preliminary Study of Disease Damage in Adult and Juvenile Myositis using the Myositis Damage Index”),

2<sup>nd</sup> Workshop, Developing Consensus on Outcomes and Clinical Trial Design Issues in Adult and Juvenile Myositis, October 22 – 23, 2002, New Orleans, LA.

The Myositis Association Annual Conference. Medical Panel: “Similarities and Differences between Adult and Juvenile Idiopathic Inflammatory Myopathies” and Workshop on “Juvenile Myositis”, September

28, 2002, Atlanta, GA.

"Scoring of the Cutaneous Manifestations of the MITAX and Myositis Damage Index"; Presentation of Sample Cases of Global Activity and Damage Ratings, and Myositis Workshop Participant in two Myositis Outcome Measure Workshops, London, England (May 2002, March 2001).

"New Developments in the Juvenile Idiopathic Inflammatory Myopathies", Grand Rounds, Department of Pediatrics, Stanford University, Palo Alto, CA, November 16, 2001.

American College of Rheumatology meeting, November 13, 2001, San Francisco, CA: Presentation of paper, "Lipodystrophy in juvenile dermatomyositis is associated with calcinosis, but not with adipocyte differentiation factor *dIk* levels

Meeting Organizer and Presentation of several papers on Core Set Outcome Measures in Adult and Juvenile Myositis, for International Workshop on Myositis Outcome Measures and Clinical Trial Design Issues: Defining Improvement in Adult and Juvenile Myositis. November 9-10, 2001, Palace Hotel, San Francisco, CA.

"Assessment of Disease Activity and Damage in Juvenile Dermatomyositis (JDM)", and Invited Participant, International Consensus Conference to Define Core Sets of Outcome Measures for Juvenile Systemic Lupus Erythematosus and Juvenile Dermatomyositis, March 30 – April 4, 2001, Pavia, Italy

"Acquired Lipodystrophy associated with Autoimmune Diseases", First International Workshop on Lipoatrophic Diabetes and other syndromes of Lipodystrophy, March 23, 2001, Bethesda, MD.

NIAMS Intramural Research Program Workshop on Pediatric Rheumatic Diseases, "Juvenile Dermatomyositis: Future Research Needs", February 16, 2001, Bethesda, MD.

Joseph L Hollander Lectureship, Division of Rheumatology, "Pathogenesis of Dermatomyositis and Polymyositis" and "Myositis-specific and Myositis-associated Autoantibodies in the Juvenile Idiopathic Inflammatory Myopathies", The Children's Hospital of Philadelphia and University of Pennsylvania, January 17, 2001, Philadelphia, PA.

American College of Rheumatology Pediatric Subsection Meeting. "Clinical and Serologic Classification of Juvenile Myositis", October 30, 2000, Philadelphia, PA.

Myositis Association of America Annual Conference. Workshop on Juvenile Myositis. October 14, 2000, Fairfax, VA.

FDA Arthritis Advisory Committee Presentation, Closed Session, Gaithersburg, MD, April 11, 2000.

NIAMS Workshop on Inflammatory Myopathies, April 5-6, 2000, Bethesda, MD: "Juvenile Myositis: Clinical Overview".

Workshop: Hands on Approach to the Diagnosis and Management of the Child with Rheumatic Disease: Juvenile Dermatomyositis. American Academy of Pediatrics meeting, Washington DC, October 10, 1999.

VI Pediatric Rheumatology European Congress/EULAR, Glasgow, Scotland, June 6, 1999: "Classification and epidemiology of the juvenile idiopathic inflammatory myopathies".

National Institutes of Health Clinical Center Grand Rounds, Bethesda, MD, May 27, 1999: "Lipodystrophy in Association with Autoimmune Disease" as part of Clinical Staff Conference: "The importance of Fat: Lipoatrophy, Insulin Resistance and Diabetes", S. Taylor, moderator.

Moderator of Concurrent Session, Immunogenetics and Autoantibodies in Pediatric Rheumatologic Diseases, American College of Rheumatology meeting, San Diego CA, November 11, 1998

American Juvenile Arthritis Organization National Conference, July 24, 1998, Arlington, VA: Medical Understanding: Juvenile Dermatomyositis and Mixed Connective Tissue Disease

Park City IV International Pediatric Rheumatology Meeting, Allied Health Professionals section, March 18, 1998, Park City, Utah, "Clinical Evaluation and Management of Childhood Myositis"

American Academy of Pediatrics, Rheumatology Subsection, November 2, 1997, New Orleans, LA: "The Spectrum of Childhood Inflammatory Myopathies"

Myositis Association of America Conference, October 4, 1997: "Workshop for parents of children with myositis".

FDA Arthritis Advisory Committee Meeting, February 4/5, 1997: "Juvenile Rheumatoid Arthritis and the Proposed Application of the Pediatric Use Regulation".

American College of Rheumatology Meeting, October 21, 1996, Orlando Florida: Presentation of paper, "Immunogenetic risk factors for juvenile idiopathic inflammatory myopathy"

Meeting Co-Chair, FDA Juvenile Rheumatoid Arthritis Workshop, July 23, 1996, Bethesda, MD

Grand Rounds, Dept of Rehabilitation Medicine, National Institutes of Health, May 19, 1995: "Juvenile dermatomyositis"

National Institutes of Health Clinical Center Grand Rounds, September 29, 1993; "Juvenile idiopathic inflammatory myopathies" as part of Clinical staff conference "Myositis: Immunologic contributions to understanding causes, therapy", P.H. Plotz, moderator.